SANUWAVE Health, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This is an annual report, not a quarterly filing. Financial statements are audited by BDO USA, LLP, which issued an unqualified opinion and highlighted substantial doubt about the Company’s ability to continue as a going concern.
Business context
SANUWAVE develops noninvasive acoustic pressure shock-wave devices for regenerative medicine. Its lead U.S. candidate, dermaPACE, is intended to treat diabetic foot ulcers; it had no commercial products for sale in the United States during the period. Revenue came primarily from CE-marked dermaPACE and orthoPACE devices and accessories sold through international distributors. The Company also describes potential orthopedic and non-medical applications, largely dependent on development, regulatory progress, or partnerships.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $965,501 | $847,367 |
| Gross profit / gross margin | $680,539 / 70% | $627,392 / 74% |
| Research and development | $2,172,819 | $3,000,807 |
| General and administrative | $2,735,129 | $3,269,033 |
| Operating loss | $(4,437,778) | $(5,963,490) |
| Net loss | $(4,810,285), or $(0.08) per share | $(5,974,080), or $(0.12) per share |
| Cash used in operating activities | $(3,473,456) | $(6,678,369) |
| Cash and cash equivalents at year-end | $152,930 | $3,547,071 |
- Revenue increased 14%, mainly from higher orthoPACE sales in Asia/Pacific and Europe and increased applicator sales. Gross margin declined because devices, which carry lower margins than applicators, made up a larger share of sales.
- Year-end working capital was negative $851,805; total assets were $958,361 and stockholders’ deficit was $5,877,836. Accumulated deficit was $92,994,408.
- Related-party notes payable were $5,348,112, net of debt discount, at year-end. HealthTronics extended the notes’ maturity to January 31, 2017, raised the interest rate to 8% effective August 1, 2015, and received a first security interest in Company assets. The agreement requires 20% of cash equity-issuance or intellectual-property licensing proceeds to prepay principal, subject to a waiver for the March 2016 offering.
Changes, outlook, and material risks
- Net loss narrowed 19% year over year, reflecting lower R&D and G&A costs. Operating cash use also declined 48%; however, the Company had no financing cash inflows in 2015, versus $10.1 million in 2014.
- The initial dermaPACE Phase III study missed its primary 12-week wound-closure endpoint. In the supplemental study, the monitoring success criterion for the 12-week endpoint was not met, and enrollment stopped at 130 patients. Combined-study results reported no statistically significant difference at 12 weeks, but wound closure at 24 weeks was 37.8% with dermaPACE versus 26.2% for control (p=0.023). The Company reported no serious or treatment-related adverse events. FDA approval remained uncertain.
- Management planned an FDA meeting in late April or early May 2016 to discuss submission strategy, followed by a formal submission. It anticipated monthly operating cash use of $175,000–$225,000 during the first two quarters of 2016, excluding FDA submission costs, and said additional capital would be needed during or before the third quarter. Failure to raise funds could force a bankruptcy filing.
- After year-end, the Company reported a March 11, 2016 equity offering of $1,529,750 gross, issuing 25,495,835 common shares and 25,495,835 warrants exercisable at $0.08. The filing also reports 96,000,308 common shares outstanding as of March 23, 2016, versus 63,056,519 at year-end 2015. Further dilution is possible.
- Other significant risks include dependence on external financing after former financial backers liquidated; reliance on a small number of distributors and single-source suppliers; uncertain reimbursement and market acceptance; and competition from better-capitalized companies. Two distributors represented 66% of 2015 revenue combined.
- Management concluded disclosure controls were ineffective because of a material weakness involving insufficient expertise and resources to account for complex financial instruments and derivatives. Remediation was designed but not yet tested for operating effectiveness.
Key facts investors should verify
- Current cash, monthly burn, FDA submission expenses, and whether financing is sufficient to fund operations beyond the third quarter of 2016.
- FDA feedback on the proposed dermaPACE submission pathway and the agency’s assessment of the full clinical data, particularly the missed 12-week endpoints and later 20- to 24-week findings.
- Debt terms and compliance, including the secured HealthTronics balance, January 2017 maturity, interest accrual, and mandatory-prepayment provisions or waivers.
- Fully diluted share count, warrant exercises and terms, and the potential dilution from the 2016 offering and outstanding securities. The filing describes Series B preferred conversion terms inconsistently; confirm the governing designation.
- Progress in remediating the material weakness, and continued dependence on concentrated distributors and suppliers.